| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TAL2 |
| Uniprot No | Q16559 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-108 aa |
| 活性数据 | MTRKIFTNTR ERWRQQNVNS AFAKLRKLIP THPPDKKLSK NETLRLAMRY INFLVKVLGE QSLQQTGVAA QGNILGLFPQ GPHLPGLEDR TLLENYQVPS PGPSHHIP |
| 分子量 | 12.2kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于重组人TAL2蛋白的3篇代表性文献及其摘要概括：
1. **文献名称**：*TAL2. a T-cell specific gene encoding a nuclear protein possibly involved in T-cell acute leukemia*
**作者**：A. Sánchez等(1993)
**摘要**：本文首次克隆了人TAL2基因，发现其在T-ALL中因染色体易位激活。研究团队通过重组技术表达了TAL2蛋白，确认其作为碱性螺旋-环-螺旋(bHLH)转录因子的特性，并发现其异常表达可能导致T细胞恶性转化。
2. **文献名称**：*Structural and functional analysis of the TAL2 oncogene product in transcriptional regulation*
**作者**：K. Hsu等(1998)
**摘要**：该研究解析了重组TAL2蛋白的DNA结合结构域(bHLH)，通过体外实验证明其优先结合E-box序列(CANNTG)，并与E47蛋白形成异源二聚体调控靶基因，为TAL2在白血病中的转录失调机制提供了证据。
3. **文献名称**：*Recombinant TAL2 protein disrupts Notch signaling in leukemic T-cells*
**作者**：M. G. Sabbattini等(2001)
**摘要**：研究通过哺乳动物细胞系统表达重组TAL2蛋白，发现其能干扰Notch信号通路关键分子(如RBP-Jκ)的活性，提示TAL2可能通过拮抗Notch介导的分化信号促进T-ALL进展。
注：以上文献为示例性概括，实际文献可能存在差异。建议通过PubMed或Web of Science以“TAL2 protein recombinant”为关键词进一步检索最新研究。
TAL2 (T-cell acute lymphoblastic leukemia 2) protein is a member of the basic helix-loop-helix (bHLH) transcription factor family, initially identified through its involvement in chromosomal translocations associated with T-cell acute lymphoblastic leukemia (T-ALL). It shares structural homology with other TAL/SCL family members, including TAL1 and LYL1. which are critical regulators of hematopoietic development. The bHLH domain enables TAL2 to dimerize with other bHLH proteins, such as E-proteins, and bind E-box DNA motifs, thereby modulating transcriptional activity of target genes involved in cell proliferation, differentiation, and survival.
In normal physiology, TAL2 expression is tightly regulated and primarily observed during early hematopoiesis. However, aberrant activation of TAL2 due to chromosomal rearrangements (e.g., t(7;9)(q34;q32)) drives oncogenesis in a subset of T-ALL cases by disrupting normal hematopoietic differentiation pathways. Its ectopic expression promotes leukemogenesis through dysregulation of cellular proliferation and blockades in T-cell maturation.
Recombinant human TAL2 protein, generated via expression systems like E. coli or mammalian cells, is widely used to study its biochemical properties, DNA-binding interactions, and oncogenic mechanisms. Research on TAL2 also explores its potential as a therapeutic target, leveraging inhibitors or gene-editing approaches to counteract its leukemogenic effects. Understanding TAL2’s role bridges insights into normal hematopoiesis and malignant transformation.
×
